335
+1.21%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Carna Biosciences
Its shares trade on Tokyo Stock Exchange under the ticker 4572.T. It has been listed since 25 March 2008. In the fiscal year to 31 December 2025, it reported revenue of ¥579.1m and a net loss of ¥2.17bn. At that date it held total assets of ¥1.23bn and shareholders' equity of ¥309.2m.
Carna Biosciences, Inc. engages in the drug discovery business. The company is headquartered in Kobe, Hyogo-Ken. The company went IPO on 2008-03-25. The firm operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 25 Mar 2008
- Employees
- 63
- Website
- carnabio.com ↗
Leadership
Pay as last reported
- Mr. Koichiro YoshinoPresident, Representative Director, since 2003
- Ms. Eimi YamamotoChief Financial Officer, Chief Director of Business Administration, Director of Accounting, Director of Human Resources and General Affairs, President of Subsidiary, Director, since 2017
- Mr. Masaaki SawaChief Scientific Officer, Director, since 2015
- Mr. Norio AikawaChief Director of New Drugs Development Support Business, Director of Intellectual Property & Legal Affairs, Director, since 2004
- Mr. Akinori ArimuraChief Development Officer, Director, since 2023
- Mr. Atsuo AritaIndependent Director
- Mr. Takao MatsuiIndependent Director
- Mr. Tsuguo OgasawaraIndependent Director
- Mr. Kaoru SuzukiIndependent Director
- Mr. Teruo TakayanagiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Carna Biosciences Inc has a strong reputation in the biotechnology industry due to its advanced research and development capabilities. The company has a highly skilled team of scientists and researchers who are dedicated to discovering innovative solutions.
- Carna Biosciences Inc possesses a diverse portfolio of patented technologies and intellectual property, giving it a competitive advantage in the market. This allows the company to develop unique products and services that meet the specific needs of its customers.
Weaknesses
- One of the weaknesses of Carna Biosciences Inc is its relatively high dependence on a limited number of key customers. This makes the company vulnerable to fluctuations in their demand and could have a negative impact on its financial performance.
- Carna Biosciences Inc faces intense competition from other biotechnology companies, both established players and emerging startups. This poses a challenge to the company in terms of maintaining market share and securing new business opportunities.
Opportunities
- The increasing demand for personalized medicine presents a significant opportunity for Carna Biosciences Inc. With its expertise in developing targeted therapeutics, the company can capitalize on this trend and offer tailored solutions to patients and healthcare providers.
- Expansion into international markets is another potential opportunity for Carna Biosciences Inc. By leveraging its strong brand and scientific expertise, the company can explore new territories and tap into a larger customer base.
Threats
- Regulatory challenges and stringent government policies can pose a threat to Carna Biosciences Inc's operations. Compliance with various regulations around the world can be complex and time-consuming, potentially affecting the company's ability to bring products to market.
- Rapid advances in technology and new entrants in the biotechnology industry pose a threat to Carna Biosciences Inc. Keeping up with the latest advancements and remaining at the forefront of innovation is essential to stay competitive in the ever-evolving market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.